 treatment aplast anemia antilymphocyt globulin methylprednisolon cyclosporin german aplast anemia studi group background and method immunosuppress effect treatment patient aplast anemia bone marrow transplant result antilymphocyt globulin cyclosporin patient combin agent control evalu efficaci trial patient elig bone marrow transplant treatment antilymphocyt globulin methylprednisolon patient control group antilymphocyt globulin methylprednisolon cyclosporin patient cyclosporin group result month patient cyclosporin group complet partial remiss respons treatment patient control group percent percent differ month percent percent superior result regimen cyclosporin evid patient sever sever aplast anemia respons rate month percent percent patient control group granulocyt hemoglobin level normal patient platelet count subnorm percent patient patient respons cyclosporin group control group month treatment actuari surviv patient month percent cyclosporin group percent control group patient sever sever diseas surviv percent percent cyclosporin substanti revers side effect conclus immunosuppress treatment aplast anemia antilymphocyt globulin methylprednisolon cyclosporin effect regimen antilymphocyt globulin methylprednisolon cyclosporin treatment choic patient elig bone marrow transplant